Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis
Journal Title: Neurology Letters - Year 2022, Vol 1, Issue 1
Abstract
Amyotrophic Lateral Sclerosis (ALS) is a progressively debilitating disease characterized by selective neurodegeneration of upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord. Degeneration of upper and lower motor neurons leads to spasticity and atrophy respectively, which begins with focal weakness and then spread to other muscles including the diaphragm, and finally died as a result of respiratory paralysis. To date, there are only two drugs approved by US Food and Drug Administration (FDA) for ALS treatment: riluzole and edaravone. The approval of only two drugs is evident of minimal progress in ALS treatment over the past decades. However, more drugs are currently under investigation, and we hope more drugs will be available for ALS treatment, but many challenges in developing new therapeutic agents may remain such as blood-brain barrier (BBB), targeting, clearance, biostability, and degradation. Advances in biomaterial proposed utilizing nanoparticles to package and delivery pharmaceuticals to CNS to protect against absorption, clearance, and facilitate the transportation across BBB. Designing and engineering nano-bio materials loaded with agents such as riluzole or other efficient substances provide prospective advances in therapeutic approaches and drug delivery systems for neurodegenerative disease, particularly ALS. Here we reviewed biomaterials used in ALS therapeutic approach over the last years.
Authors and Affiliations
Fardin Nabizadeh,
Keywords
Related Articles
- EP ID EP709695
- DOI 10.52547/nl.1.1.12
- Views 72
- Downloads 1
Diffusion tensor imaging (DTI) and plasma p-tau 181 in Alzheimer’s disease
Alzheimer’s Disease (AD) is characterized by cognitive impairments and memory difficulties, which cause daily activities, and personal and behavioral problems. In recent years blood-based biomarkers like plasma phosphory...
Neurology Letters is born!
On behalf of our editorial board, editorial team, authors, reviewers, and supporting institutions – we warmly welcome you to the first issue of the Neurology Letters. This is the official journal of the Neurology departm...
What should we do to reduce the complications of Deep brain stimulation in Parkinson's disease?
Parkinson's Disease (PD) is one of the most common neurodegenerative disorders. Recently, Deep Brain Stimulation (DBS) was proposed as a potential therapeutic approach for PD patients. This procedure has side effects tha...
Transient global amnesia associated with acute bacterial endocarditis; A case report
Introduction: Transient global amnesia (TGA) is a sudden loss of memory without definite etiology. Some cardiac conditions like myocardial infarction, mitral valve prolapse, takotsubo syndrome, and arrhythmias have been...
Antioxidant supplements and cognition in Multiple Sclerosis: a systematic review
Background: Cognitive dysfunction is a debilitating characteristic of multiple sclerosis (MS) that affects approximately 60% of patients. To date, the only effective treatments for cognitive decline are cognitive rehabil...